EMPA (drug)
 | |
| Clinical data | |
|---|---|
| ATC code | none |
| Identifiers | |
| |
| CAS Number | 680590-49-2 |
| PubChem (CID) | 9981404 |
| ChemSpider | 8156996 |
| ECHA InfoCard | 100.233.393 |
| Chemical and physical data | |
| Formula | C23H26N4O4S |
| Molar mass | 454.542 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
EMPA is a selective antagonist of the OX2 receptor, with 900-fold selectivity in binding for OX2 over OX1.[1][2]
See also
References
- ↑ "Biochemical and Electrophysiological Characterization of Almorexant, a Dual Orexin 1 Receptor (OX1)/Orexin 2 Receptor (OX2) Antagonist: Comparison with Selective OX1 and OX2 Antagonists", , Pari Malherbe, Edilio Borroni, Emmanuel Pinard, Joseph G. Wettstein, and Frederic Knoflach, in Molecular Pharmacology, , 2009
- ↑ Malherbe et al (2009) Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX2 receptor. Br.J.Pharmacol. 156 1326. PMID 19751316.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.